Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProsPERo: 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer
NCT02810886Phase 2Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Peptide-Drug Conjugates
01
Overview
A Phase 2 trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Institut Jules Bordet. Planned start Oct 2016; status: withdrawn.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02810886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810886.